Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ambrisentan + theophylline
- Development stage
- Phase 3
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of ambrisentan (a selective endothelin A receptor antagonist) and theophylline (a xanthine derivative). Ambrisentan works by relaxing blood vessels in the lungs, while theophylline relaxes smooth muscle of the bronchial airways. This combination has been studied for potential use in preventing acute mountain sickness (AMS) and improving exercise performance at high altitudes.
- Other names
- theophylline ethylenediamineaminofilinaaminophyllinum
02
Targets
ADOR (Adenosine receptors)EDNRA (Endothelin receptor type A)ADORA2B (Adenosine A2B receptor)HDAC (HDAC family)PDE (Phosphodiesterase family)
Beyond the preview
Go deeper on ambrisentan + theophylline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ambrisentan + theophylline.